Neurocrine’s Delaet now chief regulatory officer

San Diego-based Neurocrine Biosciences Inc. (NASDAQ:NBIX) promoted Ingrid Delaet to chief regulatory officer. Delaet joined Neurocrine as VP of regulatory affairs in January 2021, before which she worked at Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) and Bristol Myers Squibb Co. (NYSE:BMY). Neurocrine is developing treatments for neurological, neuroendocrine and neuropsychiatric disorders. 

Chief Development Officer Gaston Picchio will leave his position at Arbutus Biopharma Corp. (NASDAQ:ABUS) for personal reasons, effective Dec. 31. The company, which is developing treatments for viral diseases, said it had initiated a search for a replacement. ...